Takeda Pharmaceutical Company Limited

Ligand Pharmaceuticals, Inc.

Mark E Adams

Lin Zhi

Donald Karanewsky

Jason W Brown

Huikai Sun

Maria Hopkins

Betty Lam

James Patrick Edwards

Michael Brennan Wallace

Toufike Kanouni

Qing Dong

Stephen W Kaldor

Stephen A Hitchcock

Holly Reichard

Shota Kikuchi

Neelakandha S Mani

Zhe Nie

Holger Monenschein

Robert Higuchi

Nicholas Scorah

Mitsunori Kono

Srinivasa Reddy Natala

Yan Liu

Jyun-Hung Chen

Rongliang Chen

Anthony W Thompson

Thomas R Caferro

Marquis L Cummings

Charlotte L F Deckhut

Matthew Lardy

Steven James Wilkens

The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

Pyrazines as modulators of GPR6

Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

MAPK/ERK kinase inhibitors

This invention relates to compounds that bind to mineralocorticoid receptors and/or modulate activity of mineralocorticoid receptors, and to methods for making and using such compounds. Some embodiments relate to compounds of Formula I: or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein R&#x2014;Rare as defined herein.

Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses

Novel non-steroidal tricyclic quinolinone and tricyclic quinoline compounds and compositions that are agonists, partial agonists and/or antagonists for androgen receptors (AR), their preparation and their uses are described.

Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods

Growing community of inventors

San Diego, CA, United States of America

Mark E Adams